Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Canadian Institutes of Health Research (CIHR) | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Men sustain over one-third of osteoporosis-related fractures worldwide. The burden of osteoporotic fractures in older men is substantial, and men suffer significantly worse fracture-related outcomes than women. Following a fracture, men sustain greater rates of subsequent fractures, loss of autonomy, and mortality than women and the imminent risk of re-fracture is several times higher in men than in women. Functional mobility, known to predict falls and fractures, is also notably worse in men following a fracture. In the fiscal year 2007-08, the overall annual costs of osteoporosis in Canadian men was evaluated to be $910 million.
Osteoporosis is primarily considered a disease of older women, and men are remarkably under-evaluated and under-treated for it. Recognition of sex and gender influences on skeletal health in men has been very slow; akin to the gap in cardiovascular diseases, where women are far less likely to receive guideline-recommended investigations and treatment.
Over 85% of Canadian men who suffer from fragility fractures do not receive osteoporosis screening and/or treatment strategies. The existence of this care gap in men underscores our current struggle to overcome important barriers including: 1) men's lack of awareness of the critical impact of osteoporosis and fractures on several aspects of their lives, and of the benefits of treatment; and 2) the absence of comprehensive and accessible treatments tailored to men.
Informed by the Knowledge-to-Action framework, we aim to address these barriers by adapting interventions with proven efficacy to engage men at high fracture risk in health behaviour change.
The current protocol is for a pilot RCT to determine the feasibility of recruitment and retention, adherence to, and acceptability of the virtually-delivered fracture prevention intervention only.
Our long-term goal is to conduct a large pragmatic randomized controlled trial (RCT) to address the research question: In older adults at high risk for fractures who self-identify as men, does anti-osteoporosis pharmacotherapy in conjunction with a virtually-delivered intervention that includes a gender-tailored strength training and balance based exercise program and nutritional counselling, improve functional mobility compared to anti-osteoporosis pharmacotherapy in conjunction with an attention control intervention.
The current proposal for this assessor-blind parallel group multicenter pilot RCT of 12 months duration is in line with published frameworks for pilot studies in preparation for RCTs. For the pilot study, the investigators will enroll participants irrespective of anti-osteoporosis medication use.
This pilot RCT will determine the following primary feasibility objectives which will be assessed at 12 months :
The investigators will also report exploratory analyses comparing the effect of the virtual intervention group to an attention control group. Exploratory outcomes will include the number of falls and fractures, changes in physical function (measured by lower extremity strength, gait speed, and balance), fall self-efficacy, quality of life and self-management behaviors in nutrition and exercise.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Misterfit online group | Experimental | The Misterfit online group will receive a 12-month virtually-delivered fracture prevention intervention that includes a personalized gender-tailored strength training and balance-based exercise program, nutritional counselling and fall and fracture prevention education. |
|
| MisterFit offline group | Other | The Misterfit offline group will act as an attention control group receiving a fracture prevention intervention with the same components as the experimental group, but the components will not be virtual, personalized or gender-tailored. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Multifaceted Virtual Fracture Prevention Program | Behavioral |
|
| Measure | Description | Time Frame |
|---|---|---|
| Study recruitment rates (feasibility objective) | The study will be considered feasible if the investigators can recruit 12 participants per site within one year | 12 months |
| Study retention rates (feasibility objective) | The study will be considered feasible if ≥ 75 % of the sample completes the 12-month assessment | 12 months |
| Adherence to the exercise and nutrition interventions (feasibility objective) | The exercise intervention will be considered feasible if participants complete ≥ 65% of the prescribed number of exercise sessions at the 12-month follow-up. The nutrition intervention will be considered feasible if participants attend 66% of the visits. | 12 months |
| Perceived usability and satisfaction of the telehealth platform application (feasibility objective) | Measured using the the System Usability Scale (SUS) where scores range from 0 (very poor) to 100 (excellent). Usability will be deemed to be acceptable if the mean SUS score is above 68 (SUS ≥ 68 = average user experience). | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change of health-related quality of life | Measured using the multi-dimensional, self-administered EuroQol five-dimension (EQ-5D-3L) questionnaire | 0, 6, and 12 months |
| Change in social isolation |
Not provided
Community-dwelling individuals ≥ 60 years who self-identify as men will be considered eligible if their risk for fracture is evaluated to be high, defined by the presence of one of the following inclusion criteria:
Exclusion Criteria:
Community-dwelling individuals ≥ 60 years who self-identify as men
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Suzanne Morin, MD | Research Institute of the McGill University Health Centre | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Calgary | Calgary | Alberta | Canada | |||
| McMaster University |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Assessor-blind parallel group multicenter pilot RCT of 12 months duration.
Not provided
Not provided
Physical measures including balance, muscle strength, and gait speed will be recorded by an outcome assessor blind to group assignment.
|
| Attention Control | Behavioral |
|
|
Measured using the UCLA 3-Item Loneliness Scale questionnaire
| 0, 6, and 12 months |
| Change in the action planning phase of behaviour | Measured using the Health Action Process Approach (HAPA) questionnaire | 6 and 12 months |
| Change in self-efficacy, or confidence, for behaviors related to physical activity and calcium intake | Measured using the Osteoporosis Self-Efficacy Scale (OSES) questionnaire | 0, 6, and 12 months |
| Change in fear of falling in community-dwelling older adults | Measured using the seven-item self-administered Falls Efficacy Scale (FES) questionnaire | 0, 6, and 12 months |
| Change in physical activity | Measured using the Physical Activity Scale for the elderly (PASE) questionnaire | 0, 6, and 12 months |
| Change in total protein intake | Measured in grams using the Automated Self-Administered 24-Hour (ASA24®) Dietary Assessment Tool | 2, 6, and 12 months |
| Change in total calcium intake | Measured in mg using the Automated Self-Administered 24-Hour (ASA24®) Dietary Assessment Tool | 2, 6, and 12 months |
| Change in vitamin D intake | Measured in IU using the Automated Self-Administered 24-Hour (ASA24®) Dietary Assessment Tool | 2, 6, and 12 months |
| Change in functional leg muscle strength | Measured using the 30-second Chair stand test | 0 and 12 months |
| Change in gait speed | Measured using the 10-meter walk test | 0 and 12 months |
| Change in dynamic balance | Measured using the four-step square test | 0 and 12 months |
| Change in balance | Measured using the Short Form Berg Balance Scale (SF BBS-3P) | 0 and 12 months |
| Number of falls reported | Collected using falls calendar | 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 months |
| Healthcare utilization | Collected using healthcare utilization questionnaire | 0, 6 and 12 months |
| Reporting of safety outcomes (serious and non-serious adverse events) | Collected using Adverse Event Reporting | 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 months |
| Hamilton |
| Ontario |
| Canada |
| University Health Network | Toronto | Ontario | Canada |
| McGill University Health Centre | Montreal | Quebec | H4A 3J1 | Canada |
| Centre Hospitalier Universitaire de Québec | Québec | Quebec | Canada |
| ID | Term |
|---|---|
| D010024 | Osteoporosis |
| D058866 | Osteoporotic Fractures |
| D009133 | Muscular Atrophy |
| D018761 | Multiple Endocrine Neoplasia Type 1 |
| ID | Term |
|---|---|
| D001851 | Bone Diseases, Metabolic |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D050723 | Fractures, Bone |
| D014947 | Wounds and Injuries |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D001284 | Atrophy |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012816 | Signs and Symptoms |
| D009377 | Multiple Endocrine Neoplasia |
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D009378 | Neoplasms, Multiple Primary |
| D009386 | Neoplastic Syndromes, Hereditary |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D004700 | Endocrine System Diseases |
Not provided
Not provided